Abstract
Background:
Darbepoetin alfa is an erythropoietis-stimulating glycoprotein with a ∼3-fold longer t1/2 and greater biological activity compared with recombinant human erythropoietin (rHuEPO).
Objective:
The objective of this study was to evaluate the efficacy andtolerability of long-term (24-week) darbepoetin alfa treatment in maintaining hemoglobin (Hb) concentrations in the target range of 10 to 13 g/dL in patients undergoing dialysis; the patients were switched from rHuEPO to a less-frequent dosing regimen of darbepoetin alfa without an increase in dose.
Methods:
In this Phase IIlb, open-label, multicenter study, patients withend-stage renal disease (ESRD) undergoing dialysis who were receiving rHuEPO BIW or TIW at baseline were switched to darbepoetin alfa QW; patients receiving rHuEPO QW were switched to darbepoetin alfa Q2W Administration of darbepoetin alfa was by the same route as previous rHuEPO administration (IV or SC). Patients received darbepoetin alfa for 24 weeks, including a 20-week drug titration period followed by a 4-week, stable-dose evaluation period. The mode, dose, and frequency of administration of darbepoetin alfa were compared with those of baseline rHuEPO. Tolerability assessment was based on spontaneous reporting and laboratory tests (hematology, vital sign measurement, iron status, and biochemistry).
Results:
The study comprised 173 patients who were divided into 2 groups by route of administration (IV group, n = 146; SC group, n = 27). Mean (SE) adjusted increases in Hb concentration from baseline to the evaluation period for patients receiving darbepoetin alfa QW were 0.94 (0.32) g/dL and 0.38 (0.30) g/dL for the IV or SC routes, respectively (P = 0.004 and NS, respectively). For patients receiving darbepoetin alfa Q2W the mean (SE) adjusted increases in Hb concentration were 0.08 (0.53) g/dL and 0.48 (0.35) g/dL for the IV and SC routes, respectively (both, P = NS). No significant differences in IV/SC dose ratio were observed between the 2 routes of administration. In addition, no increases in darbepoetin alfa dose were observed. The most commonly reported adverse events were hypertension (8 patients [5%]) and vascular access thrombosis (4 [2%]). The incidence of treatment-related adverse events was 6 (3%).
Conclusions:
Darbepoetin alfa effectively maintained Hb concentrations within the target range without an increase in dose, even at a reduced dosing frequency. Overall, darbepoetin alfa was well tolerated.
Key words: darbepoetin alfa, dialysis, efficacy, renal disease, rHuEPO, safety, tolerability
Full Text
The Full Text of this article is available as a PDF (929.8 KB).
Footnotes
Members of the study group are listed in the Acknowledgments.
References
- 1.National Renal Disease Patient Registry, Office for Coordination and Control of CRF, Greek Ministry of Health and Welfare Bulletin of National Ministry of Health. September 24, 2003 [Google Scholar]
- 2.Krantz S.B. Erythropoietin. Blood. 1991;77:419–434. [PubMed] [Google Scholar]
- 3.Lacombe C., Mayeux P. Biology of erythropoietin. Haematologica. 1998;83:724–732. [PubMed] [Google Scholar]
- 4.Caro J., Brown S., Miller O. Erythropoietin levels in uremic, nephric and anephric patients. J Lab Clin Med. 1979;93:449–458. [PubMed] [Google Scholar]
- 5.Eschbach J.W., Egrie J.C., Downing M.R. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
- 6.Joy M.S. Darbepoetin alfa: A novel erythropoiesis-stimulating protein. Ann Pharmacother. 2002;36:1183–1192. doi: 10.1345/aph.1A416. [DOI] [PubMed] [Google Scholar]
- 7.Overbay D.K., Manley H.J. Darbepoetin alfa: A review of the literature. Pharmacotherapy. 2002;22:889–897. doi: 10.1592/phco.22.11.889.33633. [DOI] [PubMed] [Google Scholar]
- 8.Macdougall I.C. Darbepoetin alfa: A new therapeutic agent for renal anemia. Kidney Int Suppl. 2002:55–61. doi: 10.1046/j.1523-1755.61.s80.11.x. [DOI] [PubMed] [Google Scholar]
- 9.Egrie J.C., Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant. 2001;16(Suppl 3):3–13. [PubMed] [Google Scholar]
- 10.Brunkhorst R., Bommer J., Braun J., for the German Aranesp Study Group Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant. 2004;19:1224–1230. doi: 10.1093/ndt/gfh106. [DOI] [PubMed] [Google Scholar]
- 11.Egrie J.C., Dwyer E., Browne J.K. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290–299. doi: 10.1016/s0301-472x(03)00006-7. [DOI] [PubMed] [Google Scholar]
- 12.Locatelli F., Canaud B., Giacardy F. Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant humanerythropoietin (rHuEpo) Nephrol Dial Transplant. 2003;18:362–369. doi: 10.1093/ndt/18.2.362. [DOI] [PubMed] [Google Scholar]
- 13.European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 1999;14(Suppl 5):1–50. [PubMed] [Google Scholar]
- 14.International Conference on Harmonisation: Guidelines for Good Clinical Practice. April 26, 2005. http://www.ich.org [Google Scholar]
- 15.Uehlinger D.E., Gotch F.A., Sheiner L.B. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992;51:76–89. doi: 10.1038/clpt.1992.10. [DOI] [PubMed] [Google Scholar]
- 16.NeoRocormon (epoetin beta) [European summary of product characteristics] Roche Diagnostics GmbH; Penzberg, Germany: 1997. [Google Scholar]
- 17.Eprex (epoetinum alfa) [European summary of product characteristics] Janssen Cilag Ltd; Bucks, United Kingdom: 2003. [Google Scholar]
- 18.Aranesp (darbepoetin alfa) [European summary of product characteristics] Amgen Europe BV; Breda, the Netherlands: 2001. [Google Scholar]
- 19.NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30(Suppl 3):S192–S240. [PubMed] [Google Scholar]
- 20.Thiele A., Wittner M. Improved haemoglobin concentrations with IV darbepoetin alfa-case studies of haemodialysis patients. Curr Med Res Opin. 2002;18:440–444. doi: 10.1185/030079902125001182. [DOI] [PubMed] [Google Scholar]
- 21.Jacobs C., Hörl W.H., Macdougall I.C. European best practice guidelines 5: Target haemoglobin. Nephrol Dial Transplant. 2000;15(Suppl 4):15–19. [PubMed] [Google Scholar]
- 22.Amgen Anaemia Advisory Group Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia. Nephrology. 2002;7:S173–S180. [Google Scholar]
- 23.Nissenson A.R., Swan S.K., Lindberg J.S. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110–118. doi: 10.1053/ajkd.2002.33919. [DOI] [PubMed] [Google Scholar]
- 24.Graf H., Lacombe J.L., Braun J. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin when administered at a reduced dose frequency compared with recombinant human erythropoietin (rHuEpo) in dialysis patients. J Am Soc Nephrol. 2000;11:A250. Abstract. [Google Scholar]